A Phase I, Open-label, Dose-escalation, and Cohort Expansion Study to Evaluate the Safety and Immune Response to Autologous Dendritic Cells Transduced With AdGMCA9 (DC-AdGMCAIX) in Patients With Metastatic Renal Cell Carcinoma.

A Phase I, Open-label, Dose-escalation, and Cohort Expansion Study to Evaluate the Safety and Immune Response to Autologous Dendritic Cells Transduced With AdGMCA9 (DC-AdGMCAIX) in Patients With Metastatic Renal Cell Carcinoma. J Immunother. 2020 Nov/Dec; 43(9):273-282.

View in: PubMed

subject areas

Antigens, Neoplasm
Cancer Vaccines
Carbonic Anhydrase IX
Carcinoma, Renal Cell
Dendritic Cells
Disease Management
Granulocyte-Macrophage Colony-Stimulating Factor
Humans
Immunotherapy
Kidney Neoplasms
Treatment Outcome

authors with profiles

Thinle Chodon